Home
Screeners
All-In-One Screener
Dividend Income Portfolio
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
Good Companies
The Stalwarts
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances
Undervalued Predictable
Buffett-Munger
Low P/S
Low P/B
52w Low Predictable
Broadest Owned
Most Weighted
Gurus
Insiders
Market
Economic Data
Industry Overview
U.S. Treasury Yield Curve
Buffett Indicator
Global Market Valuations
Shiller P/E
Shiller P/E by Sectors
GF Value for SP500 Index
Buffett Assets Allocation
Articles
Tools
Tutorials
Support
Tutorial Session
Glaukos Corp
$
41.60
+0.95 (+2.34%)
10:08 PM EST
P/E:
At Loss
P/B:
3.29
Market Cap:
$ 1.97B
Enterprise V:
$ 1.94B
Volume:
218.14K
Avg Vol (2M):
549.13K
Add to your portfolio
Volume:
218.14K
Market Cap $:
1.97B
PE Ratio:
At Loss
Avg Vol (2-Month):
549.13K
Enterprise Value $:
1.94B
PB Ratio:
3.29
Alerts Website SEC Filings Stock Report Dataset Financial Download Tutorials
Tutorials
Add to your portfolio
PE Ratio
P/S Ratio
P/B Ratio
Price-FCF Ratio
Market Cap
Current and historical daily P/E ratio for Glaukos Corp () from 2015 to May 29 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Glaukos stock (GKOS) PE ratio as of May 29 2022 is 0.
More Details
Glaukos PE Ratio (TTM) Chart
EMBED
Glaukos PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1248
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Glaukos PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2022-05-29 | At Loss | 2022-03-28 | At Loss |
| 2022-05-27 | At Loss | 2022-03-25 | At Loss |
| 2022-05-26 | At Loss | 2022-03-24 | At Loss |
| 2022-05-25 | At Loss | 2022-03-23 | At Loss |
| 2022-05-24 | At Loss | 2022-03-22 | At Loss |
| 2022-05-23 | At Loss | 2022-03-21 | At Loss |
| 2022-05-20 | At Loss | 2022-03-18 | At Loss |
| 2022-05-19 | At Loss | 2022-03-17 | At Loss |
| 2022-05-18 | At Loss | 2022-03-16 | At Loss |
| 2022-05-17 | At Loss | 2022-03-15 | At Loss |
| 2022-05-16 | At Loss | 2022-03-14 | At Loss |
| 2022-05-13 | At Loss | 2022-03-11 | At Loss |
| 2022-05-12 | At Loss | 2022-03-10 | At Loss |
| 2022-05-11 | At Loss | 2022-03-09 | At Loss |
| 2022-05-10 | At Loss | 2022-03-08 | At Loss |
| 2022-05-09 | At Loss | 2022-03-07 | At Loss |
| 2022-05-06 | At Loss | 2022-03-04 | At Loss |
| 2022-05-05 | At Loss | 2022-03-03 | At Loss |
| 2022-05-04 | At Loss | 2022-03-02 | At Loss |
| 2022-05-03 | At Loss | 2022-03-01 | At Loss |
| 2022-05-02 | At Loss | 2022-02-28 | At Loss |
| 2022-04-29 | At Loss | 2022-02-25 | At Loss |
| 2022-04-28 | At Loss | 2022-02-24 | At Loss |
| 2022-04-27 | At Loss | 2022-02-23 | At Loss |
| 2022-04-26 | At Loss | 2022-02-22 | At Loss |
| 2022-04-25 | At Loss | 2022-02-21 | At Loss |
| 2022-04-22 | At Loss | 2022-02-18 | At Loss |
| 2022-04-21 | At Loss | 2022-02-17 | At Loss |
| 2022-04-20 | At Loss | 2022-02-16 | At Loss |
| 2022-04-19 | At Loss | 2022-02-15 | At Loss |
| 2022-04-18 | At Loss | 2022-02-14 | At Loss |
| 2022-04-15 | At Loss | 2022-02-11 | At Loss |
| 2022-04-14 | At Loss | 2022-02-10 | At Loss |
| 2022-04-13 | At Loss | 2022-02-09 | At Loss |
| 2022-04-12 | At Loss | 2022-02-08 | At Loss |
| 2022-04-11 | At Loss | 2022-02-07 | At Loss |
| 2022-04-08 | At Loss | 2022-02-04 | At Loss |
| 2022-04-07 | At Loss | 2022-02-03 | At Loss |
| 2022-04-06 | At Loss | 2022-02-02 | At Loss |
| 2022-04-05 | At Loss | 2022-02-01 | At Loss |
| 2022-04-04 | At Loss | 2022-01-31 | At Loss |
| 2022-04-01 | At Loss | 2022-01-28 | At Loss |
| 2022-03-31 | At Loss | 2022-01-27 | At Loss |
| 2022-03-30 | At Loss | 2022-01-26 | At Loss |
| 2022-03-29 | At Loss | 2022-01-25 | At Loss |
Glaukos PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Industry
Compare
Traded in other countries / regions
Address
229 Avenida Fabricante, San Clemente, CA, USA, 92672
Website
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Affiliate Program
Get WordPress Plugins
for easy affiliate links on Stock Tickers and Guru Names
GuruFocus Affiliate Program: Earn up to $400 per referral.
Detailed
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.
© 2004-2022 GuruFocus.com, LLC. All Rights Reserved.